Document Detail


A combination therapy using IL-12 and soluble IL-4 receptor on herpes simplex virus Type 1 infection in a human-SCID chimera model of thermal injury.
MedLine Citation:
PMID:  12498818     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Herpes simplex virus type 1 (HSV-1) is a severe pathogen in thermally injured patients. Type 1 T cells are essential for the host's anti-HSV protective immunity. Type 2 cytokines, commonly detected in thermally injured patients, have been described as inhibitors for the type 1 T cell generation. Therefore, the antiviral effects of combination therapy with a type 1 T cell inducer [interleukin (IL)-12] and a type 2 T cell inhibitor [soluble IL-4 receptor (sIL-4R)] were investigated in severe combined immunodeficiency (SCID) mice inoculated with peripheral blood lymphocytes (PBL) of thermally injured patients. Patient PBL-SCID chimeras (SCID mice inoculated with patient PBL) were susceptible to infection with 1 x 10(3) PFU/kg of HSV-1 (0% survival), while healthy PBL-SCID chimeras (SCID mice inoculated with PBL from healthy donors) were resistant (92% survival). When patient PBL-SCID chimeras exposed to HSV-1 were treated with saline, human recombinant (r) IL-12 or human sIL-4R, 0, 0, or 12.5% of them survived, respectively. However, 75% of these chimeras survived when they were treated with rIL-12 and sIL-4R in combination. These results indicate that HSV-1 infection in patient PBL-SCID chimeras was therapeutically controlled by the inducer of type 1 T cell responses and the inhibitor of type 2 T cell responses in combination.
Authors:
Tatsushi Katakura; Makiko Kobayashi; Kazuhiko Fujita; David N Herndon; Richard B Pollard; Fujio Suzuki
Related Documents :
10512068 - Thalidomide-induced toxic epidermal necrolysis.
9431978 - Low sensitivity of peripheral blood smear for diagnosis of subclinical visceral leishma...
19570078 - Human t-cell lymphotropic virus type 1 infective dermatitis emerging in adulthood.
20948738 - Cardiovascular, renal and liver events associated with human immunodeficiency virus typ...
18675568 - Seroprevalence of caprine arthritis-encephalitis virus in goats in the cariri region, p...
22475498 - Eps® 7630 (umckaloabo®), an extract from pelargonium sidoides roots, exerts anti-infl...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Clinical immunology (Orlando, Fla.)     Volume:  105     ISSN:  1521-6616     ISO Abbreviation:  Clin. Immunol.     Publication Date:  2002 Dec 
Date Detail:
Created Date:  2002-12-24     Completed Date:  2003-02-03     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  100883537     Medline TA:  Clin Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  363-70     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Burns / complications*
Chimera
Drug Therapy, Combination
Herpes Simplex / complications,  drug therapy*
Herpesvirus 1, Human*
Humans
Interleukin-12 / therapeutic use*
Lymphocytes
Male
Mice
Mice, SCID
Receptors, Interleukin-4 / therapeutic use*
Recombinant Proteins / therapeutic use
Spleen / immunology
Grant Support
ID/Acronym/Agency:
R01 AI44218-01/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Receptors, Interleukin-4; 0/Recombinant Proteins; 187348-17-0/Interleukin-12

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Streptococcal cell wall arthritis: kinetics of immune cell activation in inflammatory arthritis.
Next Document:  Transition to nonpenetrating trabecular surgery: sclerotrabeculectomy.